Pipeline and Status

The chart below illustrates the status of SAJE’s pipeline programs for the drugs and disease models that have been completed to date. SPL-850 and SPL-891.1 have been and are being studied in other animal models of disease. The drug candidates below are being tested in various models of disease using many routes of administration with accompanying PK/PD studies. Safety studies have begun for SPL-850 and SPL-891.1. SPL-334.1 has use patent protection and not composition of matter protection as do SPL-850 and SPL-891.1. Therefore, SAJE has stopped further safety studies of SPL-334.1.

Drug Candidate GSNOR Inhibition In Vitro Indication Route Animal Studies In Vivo
SPL-334.1 + IPF
Asthma
Inflammation
Cardiac Arr.
P.O.
P.O.
I.V./I.P./P.O.
I.V.
+
+
+
+
SPL-850 + Inflammation
Crohn's Dis.
Diabetes
Stroke
I.V./P.O.
P.O.
P.O.
I.V.
+
+
+
+
SPL-889 + Inflammation I.V./P.O. +
SPL-890 + Inflammation I.V./P.O. +
SPL-891.1 + Inflammation
IPF
NASH
Rheumatoid
Diabetes
Crohn's Dis.
Heart Failure
Stroke
I.V./P.O.
I.P.
I.P.
I.P.
P.O.
P.O.
I.P.
I.V.
+
+
+
+
+
+
+
+